

TDMS No. 99024 - 08
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS

Androstenedione
CAS Number: 63-05-8

Date Report Requested: 05/09/2008
Time Report Requested: 12:55:58
First Dose M/F: 12/16/02 / 12/16/02
Lab: SRI

F1_M3

C Number: C99024C
Lock Date: 06/29/2006
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Both
TDMSE Version: 2.0.0

TDMS No. 99024 - 08
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
Androstenedione
CAS Number: 63-05-8

Date Report Requested: 05/09/2008
Time Report Requested: 12:55:58
First Dose M/F: 12/16/02 / 12/16/02
Lab: SRI

HISTORICAL CONTROL STUDIES From October 2007 Report

SAME ROUTE

91005-08 -- Methylene blue trihydrate (GAVAGE METHYLCELLULOSE)

ALL ROUTES

88138-04 -- Benzophenone (ORAL FEED)
99027-04 -- Chromium picolinate monohydrate (ORAL FEED)
05174-06 -- Cresols (ORAL FEED)
96011-06 -- Cumene (INHALATION AIR)
97003-08 -- 1,2-Dibromo-2,4-dicyanobutane (SKIN ETHANOL)
93020-08 -- Diisopropylcarbodiimide (SKIN ETHANOL)
88004-06 -- Divinylbenzene (INHALATION AIR)
88123-07 -- Formamide (GAVAGE WATER)
95011-06 -- 5-(Hydroxymethyl)-2-furfural (GAVAGE WATER)
88105-04 -- Isoeugenol (GAVAGE CORN OIL)
97006-02 -- Methyl isobutyl ketone (INHALATION AIR)
91005-08 -- Methylene blue trihydrate (GAVAGE METHYLCELLULOSE)
92012-06 -- 2-Methylimidazole (ORAL FEED)
92013-06 -- 4-Methylimidazole (ORAL FEED)
88006-04 -- alpha-Methylstyrene (INHALATION AIR)
99023-04 -- beta-Myrcene (GAVAGE CORN OIL)
97008-06 -- Propargyl alcohol (INHALATION AIR)
20114-06 -- Sodium dichromate dihydrate (VI) (ORAL WATER)
96001-06 -- Stoddard solvent (type IIC) (INHALATION AIR)
05109-14 -- Triethanolamine (SKIN ACETONE)
96019-06 -- Water disinfection byproducts (Bromochloroacetic acid) (ORAL WATER)
96018-04 -- Water disinfection byproducts (Bromodichloromethane) (ORAL WATER)
96017-06 -- Water disinfection byproducts (Dibromoacetic acid) (ORAL WATER)
96015-06 -- Water disinfection byproducts (Dibromoacetonitrile) (ORAL WATER)

TDMS No. 99024 - 08
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
Androstenedione
CAS Number: 63-05-8

Date Report Requested: 05/09/2008
Time Report Requested: 12:55:58
First Dose M/F: 12/16/02 / 12/16/02
Lab: SRI

HISTORICAL CONTROL STUDIES
From October 2007 Report

96010-04 -- Water disinfection byproducts (Sodium chlorate) (ORAL WATER)

TDMS No. 99024 - 08
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
Androstenedione
CAS Number: 63-05-8

Date Report Requested: 05/09/2008
Time Report Requested: 12:55:58
First Dose M/F: 12/16/02 / 12/16/02
Lab: SRI

**FOR ALL DOSES THE TUMOR RATES IN THE FOLLOWING TISSUES/ORGANS ARE BASED ON NUMBER OF TISSUES EXAMINED.
IN OTHER TISSUES/ORGANS RATES ARE BASED ON THE NUMBER OF ANIMALS NECROPSIED.**

Adrenal Cortex
Adrenal Medulla
Bone Marrow
Gallbladder
Islets, Pancreatic
Kidney
Liver
Lung
Ovary
Pancreas
Pituitary Gland
Spleen
Testes
Thyroid Gland
Urinary Bladder

TDMS No. 99024 - 08
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
Androstenedione
CAS Number: 63-05-8

Date Report Requested: 05/09/2008
Time Report Requested: 12:55:58
First Dose M/F: 12/16/02 / 12/16/02
Lab: SRI

SUMMARY OF STATISTICALLY SIGNIFICANT ($P \leq .05$) RESULTS IN THE ANALYSIS OF Androstenedione

MALE MICE

Organ

Intestine Small: Site Unspecified
Liver

Lung
Spleen
All Organs

FEMALE MICE

Organ

Islets, Pancreatic
Liver

Lung

Skin

Thyroid Gland: Follicular Cell
All Organs

Morphology

Carcinoma
Hepatocellular Adenoma
Hepatocellular Carcinoma or Hepatoblastoma
Hepatocellular Carcinoma or Hepatocellular Adenoma
Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma
Alveolar/Bronchiolar Carcinoma
Hemangiosarcoma
Benign Tumors
Malignant and Benign Tumors

Morphology

Adenoma
Hepatocellular Adenoma
Hepatocellular Carcinoma
Hepatocellular Carcinoma or Hepatoblastoma
Hepatocellular Carcinoma or Hepatocellular Adenoma
Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma
Alveolar/Bronchiolar Adenoma
Alveolar/Bronchiolar Carcinoma
Fibroma, Fibrosarcoma, Sarcoma, Myxoma, Myxosarcoma, or Fibrous Histiocytoma
Fibrosarcoma
Fibrosarcoma, Sarcoma, Myxosarcoma, or Fibrous Histiocytoma
Carcinoma or Adenoma
Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed, NOS, or Undifferentiated Cell Type
Malignant Tumors

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Adrenal Cortex
 Adenoma**

TUMOR RATES

OVERALL (a)	1/50 (2%)	5/49 (10%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	1/43.3	5/47.36	1/44.32	1/45.17
POLY-3 PERCENT (g)	2.3%	10.6%	2.3%	2.2%
TERMINAL (d)	1/36 (3%)	5/43 (12%)	1/34 (3%)	1/37 (3%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	729 (T)
HC TUMORS SAME RTE	5/48 (10%)			
HC TUMORS ALL RTES	74/1142 (7%)			

STATISTICAL TESTS

POLY 3	P=0.289N	P=0.124	P=0.756N	P=0.751N
POLY 1.5	P=0.297N	P=0.113	P=0.759N	P=0.755N
POLY 6	P=0.279N	P=0.138	P=0.752N	P=0.746N
COCH-ARM / FISHERS	P=0.312N	P=0.098	P=0.753N	P=0.753N
MAX-ISO-POLY-3	P=0.264N	P=0.066	P=0.493N	P=0.487N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG
Harderian Gland Adenoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	7/50 (14%)	9/50 (18%)	7/50 (14%)	4/50 (8%)
POLY-3 RATE (b)	7/43.99	9/48.39	7/44.79	4/45.24
POLY-3 PERCENT (g)	15.9%	18.6%	15.6%	8.8%
TERMINAL (d)	6/36 (17%)	8/44 (18%)	5/34 (15%)	3/37 (8%)
FIRST INCIDENCE	489	721	660	712
HC TUMORS SAME RTE	8/50 (16%)			
HC TUMORS ALL RTEs	152/1149 (13%)			

STATISTICAL TESTS

POLY 3	P=0.145N	P=0.474	P=0.600N	P=0.244N
POLY 1.5	P=0.146N	P=0.441	P=0.611N	P=0.252N
POLY 6	P=0.143N	P=0.514	P=0.584N	P=0.234N
COCH-ARM / FISHERS	P=0.147N	P=0.393	P=0.613N	P=0.262N
MAX-ISO-POLY-3	P=0.219N	P=0.372	P=0.485N	P=0.159N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTEs	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG
Harderian Gland Carcinoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	3/50 (6%)
POLY-3 RATE (b)	2/43.3	0/48.36	0/44.32	3/45.97
POLY-3 PERCENT (g)	4.6%	0%	0%	6.5%
TERMINAL (d)	2/36 (6%)	0/44 (0%)	0/34 (0%)	1/37 (3%)
FIRST INCIDENCE	729 (T)	---	---	513
HC TUMORS SAME RTE	3/50 (6%)			
HC TUMORS ALL RTES	30/1149 (3%)			

STATISTICAL TESTS

POLY 3	P=0.188	P=0.214N	P=0.232N	P=0.527
POLY 1.5	P=0.192	P=0.223N	P=0.235N	P=0.516
POLY 6	P=0.184	P=0.203N	P=0.228N	P=0.541
COCH-ARM / FISHERS	P=0.198	P=0.247N	P=0.247N	P=0.500
MAX-ISO-POLY-3	P=0.125	P=0.076N	P=0.076N	P=0.352
HISTCONT SAME RTE	P=0.199	(e)	(e)	P=0.510
HISTCONT ALL RTES	P=0.143	(e)	(e)	P=0.218

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Harderian Gland
 Carcinoma or Adenoma**

TUMOR RATES	#	#	#	#
OVERALL (a)	9/50 (18%)	9/50 (18%)	7/50 (14%)	7/50 (14%)
POLY-3 RATE (b)	9/43.99	9/48.39	7/44.79	7/46.04
POLY-3 PERCENT (g)	20.5%	18.6%	15.6%	15.2%
TERMINAL (d)	8/36 (22%)	8/44 (18%)	5/34 (15%)	4/37 (11%)
FIRST INCIDENCE	489	721	660	513
HC TUMORS SAME RTE	11/50 (22%)			
HC TUMORS ALL RTES	176/1149 (15%)			

STATISTICAL TESTS

POLY 3	P=0.311N	P=0.515N	P=0.376N	P=0.354N
POLY 1.5	P=0.316N	P=0.551N	P=0.389N	P=0.370N
POLY 6	P=0.305N	P=0.472N	P=0.358N	P=0.332N
COCH-ARM / FISHERS	P=0.321N	P=0.602N	P=0.393N	P=0.393N
MAX-ISO-POLY-3	P=0.424N	P=0.413N	P=0.280N	P=0.263N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG
Intestine Small: Jejunum Carcinoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	0/50 (0%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	1/43.3	0/48.36	2/44.32	1/45.17
POLY-3 PERCENT (g)	2.3%	0%	4.5%	2.2%
TERMINAL (d)	1/36 (3%)	0/44 (0%)	2/34 (6%)	1/37 (3%)
FIRST INCIDENCE	729 (T)	---	729 (T)	729 (T)
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	14/1149 (1%)			

STATISTICAL TESTS

POLY 3	P=0.547	P=0.478N	P=0.508	P=0.751N
POLY 1.5	P=0.550	P=0.487N	P=0.503	P=0.755N
POLY 6	P=0.543	P=0.468N	P=0.515	P=0.746N
COCH-ARM / FISHERS	P=0.554	P=0.500N	P=0.500	P=0.753N
MAX-ISO-POLY-3	P=0.392	P=0.158N	P=0.290	P=0.487N
HISTCONT SAME RTE	P=0.274	(e)	P=0.135	P=0.218
HISTCONT ALL RTES	P=0.438	(e)	P=0.168	P=0.475

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Intestine Small: Site Unspecified
 Carcinoma**

TUMOR RATES	#	#	#	#
OVERALL (a)	3/50 (6%)	0/50 (0%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	3/43.3	0/48.36	2/44.32	1/45.17
POLY-3 PERCENT (g)	6.9%	0%	4.5%	2.2%
TERMINAL (d)	3/36 (8%)	0/44 (0%)	2/34 (6%)	1/37 (3%)
FIRST INCIDENCE	729 (T)	---	729 (T)	729 (T)
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	18/1149 (2%)			

STATISTICAL TESTS

POLY 3	P=0.388N	P=0.100N	P=0.489N	P=0.290N
POLY 1.5	P=0.380N	P=0.107N	P=0.496N	P=0.296N
POLY 6	P=0.397N	P=0.093N	P=0.481N	P=0.282N
COCH-ARM / FISHERS	P=0.370N	P=0.121N	P=0.500N	P=0.309N
MAX-ISO-POLY-3	P=0.181N	P=0.038N*	P=0.316N	P=0.148N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Islets, Pancreatic
 Adenoma**

TUMOR RATES

OVERALL (a)	2/50 (4%)	2/50 (4%)	2/50 (4%)	5/49 (10%)
POLY-3 RATE (b)	2/43.3	2/48.36	2/44.7	5/45.02
POLY-3 PERCENT (g)	4.6%	4.1%	4.5%	11.1%
TERMINAL (d)	2/36 (6%)	2/44 (5%)	1/34 (3%)	4/37 (11%)
FIRST INCIDENCE	729 (T)	729 (T)	620	493
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	11/1136 (1%)			

STATISTICAL TESTS

POLY 3	P=0.104	P=0.653N	P=0.683N	P=0.232
POLY 1.5	P=0.103	P=0.670N	P=0.689N	P=0.222
POLY 6	P=0.105	P=0.634N	P=0.674N	P=0.244
COCH-ARM / FISHERS	P=0.101	P=0.691N	P=0.691N	P=0.210
MAX-ISO-POLY-3	P=0.160	P=0.457N	P=0.486N	P=0.135
HISTCONT SAME RTE	P=0.070	P=0.240	P=0.212	P=0.136
HISTCONT ALL RTES	P<0.001**	P=0.112	P=0.107	P=0.003**

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG
Liver Hemangiosarcoma				
TUMOR RATES				
OVERALL (a)	3/50 (6%)	1/50 (2%)	5/50 (10%)	3/50 (6%)
POLY-3 RATE (b)	3/43.71	1/48.36	5/44.33	3/45.32
POLY-3 PERCENT (g)	6.9%	2.1%	11.3%	6.6%
TERMINAL (d)	2/36 (6%)	1/44 (2%)	4/34 (12%)	2/37 (5%)
FIRST INCIDENCE	610	729 (T)	725	690
HC TUMORS SAME RTE	2/50 (4%)			
HC TUMORS ALL RTES	30/1146 (3%)			

STATISTICAL TESTS

POLY 3	P=0.459	P=0.270N	P=0.364	P=0.646N
POLY 1.5	P=0.463	P=0.284N	P=0.358	P=0.652N
POLY 6	P=0.455	P=0.255N	P=0.370	P=0.637N
COCH-ARM / FISHERS	P=0.468	P=0.309N	P=0.357	P=0.661N
MAX-ISO-POLY-3	P=0.322	P=0.142N	P=0.239	P=0.481N
HISTCONT SAME RTE	P=0.306	P=1.000	P=0.142	P=0.237
HISTCONT ALL RTES	P=0.093	P=1.000	P=0.039*	P=0.219

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver
 Hepatoblastoma

TUMOR RATES

OVERALL (a)	3/50 (6%)	8/50 (16%)	7/50 (14%)	8/50 (16%)
POLY-3 RATE (b)	3/43.3	8/48.82	7/44.67	8/45.49
POLY-3 PERCENT (g)	6.9%	16.4%	15.7%	17.6%
TERMINAL (d)	3/36 (8%)	7/44 (16%)	6/34 (18%)	6/37 (16%)
FIRST INCIDENCE	729 (T)	593	631	648
HC TUMORS SAME RTE	2/50 (4%)			
HC TUMORS ALL RTES	43/1146 (4%)			

STATISTICAL TESTS

POLY 3	P=0.182	P=0.141	P=0.169	P=0.114
POLY 1.5	P=0.177	P=0.123	P=0.162	P=0.107
POLY 6	P=0.188	P=0.165	P=0.179	P=0.123
COCH-ARM / FISHERS	P=0.170	P=0.100	P=0.159	P=0.100
MAX-ISO-POLY-3	P=0.132	P=0.094	P=0.101	P=0.067
HISTCONT SAME RTE	P=0.184	P=0.158	P=0.159	P=0.116
HISTCONT ALL RTES	P=0.026*	P=0.107	P=0.117	P=0.075

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver
 Hepatocellular Adenoma

TUMOR RATES

OVERALL (a)	32/50 (64%)	38/50 (76%)	29/50 (58%)	43/50 (86%)
POLY-3 RATE (b)	32/44.97	38/48.36	29/45.37	43/46.84
POLY-3 PERCENT (g)	71.2%	78.6%	63.9%	91.8%
TERMINAL (d)	27/36 (75%)	38/44 (86%)	25/34 (74%)	36/37 (97%)
FIRST INCIDENCE	597	729 (T)	613	554
HC TUMORS SAME RTE	28/50 (56%)			
HC TUMORS ALL RTES	544/1146 (48%)			

STATISTICAL TESTS

POLY 3	P=0.009**	P=0.270	P=0.298N	P=0.005**
POLY 1.5	P=0.010**	P=0.211	P=0.327N	P=0.006**
POLY 6	P=0.008**	P=0.335	P=0.269N	P=0.005**
COCH-ARM / FISHERS	P=0.017*	P=0.138	P=0.341N	P=0.010**
MAX-ISO-POLY-3	P=0.011*	P=0.203	P=0.224N	P=0.002**
HISTCONT SAME RTE	P=0.019*	P=0.128	P=0.543	P=0.005**
HISTCONT ALL RTES	P=0.006**	P=0.108	P=0.337	P=0.003**

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Liver
 Hepatocellular Carcinoma**

TUMOR RATES

OVERALL (a)	26/50 (52%)	33/50 (66%)	28/50 (56%)	32/50 (64%)
POLY-3 RATE (b)	26/48.15	33/49.97	28/47.66	32/48.66
POLY-3 PERCENT (g)	54%	66%	58.7%	65.8%
TERMINAL (d)	16/36 (44%)	28/44 (64%)	16/34 (47%)	22/37 (60%)
FIRST INCIDENCE	398	593	472	485
HC TUMORS SAME RTE	13/50 (26%)			
HC TUMORS ALL RTES	317/1146 (28%)			

STATISTICAL TESTS

POLY 3	P=0.225	P=0.155	P=0.397	P=0.163
POLY 1.5	P=0.227	P=0.135	P=0.391	P=0.159
POLY 6	P=0.228	P=0.181	P=0.415	P=0.172
COCH-ARM / FISHERS	P=0.232	P=0.111	P=0.421	P=0.156
MAX-ISO-POLY-3	P=0.189	P=0.115	P=0.320	P=0.118
HISTCONT SAME RTE	P=0.104	P=0.129	P=0.157	P=0.125
HISTCONT ALL RTES	P<0.001**	P=0.013*	P=0.035*	P=0.015*

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Liver
 Hepatocellular Carcinoma or Hepatoblastoma**

TUMOR RATES

OVERALL (a)	27/50 (54%)	35/50 (70%)	30/50 (60%)	36/50 (72%)
POLY-3 RATE (b)	27/48.15	35/49.97	30/48.02	36/48.66
POLY-3 PERCENT (g)	56.1%	70.1%	62.5%	74%
TERMINAL (d)	17/36 (47%)	30/44 (68%)	17/34 (50%)	26/37 (70%)
FIRST INCIDENCE	398	593	472	485
HC TUMORS SAME RTE	15/50 (30%)			
HC TUMORS ALL RTES	346/1146 (30%)			

STATISTICAL TESTS

POLY 3	P=0.077	P=0.108	P=0.333	P=0.047*
POLY 1.5	P=0.078	P=0.093	P=0.320	P=0.046*
POLY 6	P=0.077	P=0.130	P=0.362	P=0.051
COCH-ARM / FISHERS	P=0.084	P=0.074	P=0.343	P=0.048*
MAX-ISO-POLY-3	P=0.049*	P=0.078	P=0.262	P=0.030*
HISTCONT SAME RTE	P=0.083	P=0.124	P=0.148	P=0.053
HISTCONT ALL RTES	P<0.001**	P=0.017*	P=0.043*	P=0.013*

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Liver
 Hepatocellular Carcinoma or Hepatocellular Adenoma**

TUMOR RATES

OVERALL (a)	41/50 (82%)	47/50 (94%)	42/50 (84%)	48/50 (96%)
POLY-3 RATE (b)	41/48.15	47/49.97	42/47.78	48/48.72
POLY-3 PERCENT (g)	85.2%	94.1%	87.9%	98.5%
TERMINAL (d)	31/36 (86%)	42/44 (96%)	29/34 (85%)	37/37 (100%)
FIRST INCIDENCE	398	593	472	485
HC TUMORS SAME RTE	37/50 (74%)			
HC TUMORS ALL RTEs	729/1146 (64%)			

STATISTICAL TESTS

POLY 3	P=0.025*	P=0.122	P=0.460	P=0.012*
POLY 1.5	P=0.030*	P=0.090	P=0.441	P=0.015*
POLY 6	P=0.024*	P=0.176	P=0.517	P=0.012*
COCH-ARM / FISHERS	P=0.051	P=0.061	P=0.500	P=0.026*
MAX-ISO-POLY-3	P=0.010**	P=0.068	P=0.341	P=0.004**
HISTCONT SAME RTE	P=0.018*	P=0.118	P=0.138	P=0.007**
HISTCONT ALL RTEs	P=0.009**	P=0.077	P=0.176	P=0.004**

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver
 Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma

TUMOR RATES

OVERALL (a)	41/50 (82%)	47/50 (94%)	43/50 (86%)	48/50 (96%)
POLY-3 RATE (b)	41/48.15	47/49.97	43/48.13	48/48.72
POLY-3 PERCENT (g)	85.2%	94.1%	89.4%	98.5%
TERMINAL (d)	31/36 (86%)	42/44 (96%)	29/34 (85%)	37/37 (100%)
FIRST INCIDENCE	398	593	472	485
HC TUMORS SAME RTE	38/50 (76%)			
HC TUMORS ALL RTES	740/1146 (65%)			

STATISTICAL TESTS

POLY 3	P=0.024*	P=0.122	P=0.374	P=0.012*
POLY 1.5	P=0.028*	P=0.090	P=0.342	P=0.015*
POLY 6	P=0.023*	P=0.176	P=0.454	P=0.012*
COCH-ARM / FISHERS	P=0.048*	P=0.061	P=0.393	P=0.026*
MAX-ISO-POLY-3	P=0.009**	P=0.068	P=0.263	P=0.004**
HISTCONT SAME RTE	P=0.017*	P=0.118	P=0.124	P=0.007**
HISTCONT ALL RTES	P=0.010**	P=0.077	P=0.175	P=0.004**

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Lung
 Alveolar/Bronchiolar Adenoma**

TUMOR RATES

OVERALL (a)	7/50 (14%)	7/50 (14%)	7/50 (14%)	5/50 (10%)
POLY-3 RATE (b)	7/43.3	7/48.64	7/44.4	5/46.28
POLY-3 PERCENT (g)	16.2%	14.4%	15.8%	10.8%
TERMINAL (d)	7/36 (19%)	6/44 (14%)	6/34 (18%)	2/37 (5%)
FIRST INCIDENCE	729 (T)	652	708	526
HC TUMORS SAME RTE	11/50 (22%)			
HC TUMORS ALL RTES	209/1148 (18%)			

STATISTICAL TESTS

POLY 3	P=0.287N	P=0.521N	P=0.594N	P=0.333N
POLY 1.5	P=0.296N	P=0.559N	P=0.607N	P=0.352N
POLY 6	P=0.278N	P=0.477N	P=0.579N	P=0.308N
COCH-ARM / FISHERS	P=0.307N	P=0.613N	P=0.613N	P=0.380N
MAX-ISO-POLY-3	P=0.395N	P=0.410N	P=0.479N	P=0.237N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Lung
 Alveolar/Bronchiolar Carcinoma**

TUMOR RATES

OVERALL (a)	11/50 (22%)	9/50 (18%)	4/50 (8%)	13/50 (26%)
POLY-3 RATE (b)	11/44.56	9/48.82	4/44.4	13/45.4
POLY-3 PERCENT (g)	24.7%	18.4%	9%	28.6%
TERMINAL (d)	7/36 (19%)	7/44 (16%)	3/34 (9%)	11/37 (30%)
FIRST INCIDENCE	581	606	708	688
HC TUMORS SAME RTE	1/50 (2%)			
HC TUMORS ALL RTES	115/1148 (10%)			

STATISTICAL TESTS

POLY 3	P=0.244	P=0.316N	P=0.043N*	P=0.427
POLY 1.5	P=0.252	P=0.348N	P=0.044N*	P=0.420
POLY 6	P=0.234	P=0.283N	P=0.042N*	P=0.432
COCH-ARM / FISHERS	P=0.263	P=0.402N	P=0.045N*	P=0.408
MAX-ISO-POLY-3	P=0.150	P=0.242N	P=0.023N*	P=0.337
HISTCONT SAME RTE	P=0.119	P=0.297	P=0.525	P=0.155
HISTCONT ALL RTES	P=0.015*	P=0.212	P=1.000	P=0.036*

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Lung
 Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma**

TUMOR RATES

OVERALL (a)	16/50 (32%)	15/50 (30%)	10/50 (20%)	17/50 (34%)
POLY-3 RATE (b)	16/44.56	15/49.1	10/44.4	17/46.5
POLY-3 PERCENT (g)	35.9%	30.6%	22.5%	36.6%
TERMINAL (d)	12/36 (33%)	12/44 (27%)	9/34 (27%)	12/37 (32%)
FIRST INCIDENCE	581	606	708	526
HC TUMORS SAME RTE	12/50 (24%)			
HC TUMORS ALL RTES	309/1148 (27%)			

STATISTICAL TESTS

POLY 3	P=0.422	P=0.371N	P=0.122N	P=0.561
POLY 1.5	P=0.421	P=0.421N	P=0.126N	P=0.537
POLY 6	P=0.424	P=0.319N	P=0.119N	P=0.585N
COCH-ARM / FISHERS	P=0.418	P=0.500N	P=0.127N	P=0.500
MAX-ISO-POLY-3	P=0.397	P=0.300N	P=0.081N	P=0.474
HISTCONT SAME RTE	P=0.324	P=0.465	P=1.000	P=0.191
HISTCONT ALL RTES	P=0.363	P=0.537	P=1.000	P=0.246

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG
Mammary Gland Carcinoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.3	0/48.36	0/44.32	0/45.17
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	1/1149 (0%)			

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Mammary Gland
 Carcinoma or Adenoma**

TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.3	0/48.36	0/44.32	0/45.17
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	1/1149 (0%)			

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Mammary Gland
 Fibroma, Fibroadenoma, Carcinoma, or Adenoma**

TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.3	0/48.36	0/44.32	0/45.17
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	1/1149 (0%)			

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Pituitary Gland: Pars Distalis or Unspecified Site
 Adenoma**

TUMOR RATES

OVERALL (a)	0/50 (0%)	0/49 (0%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.3	0/47.36	0/43.33	0/45.17
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/43 (0%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	3/1119 (0%)			

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG
Skeletal Muscle Sarcoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/43.76	0/48.36	0/44.32	0/45.17
POLY-3 PERCENT (g)	2.3%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	590	---	---	---
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	0/1149 (0%)			

STATISTICAL TESTS

POLY 3	P=0.408N	P=0.480N	P=0.497N	P=0.494N
POLY 1.5	P=0.403N	P=0.488N	P=0.500N	P=0.496N
POLY 6	P=0.415N	P=0.471N	P=0.495N	P=0.491N
COCH-ARM / FISHERS	P=0.394N	P=0.500N	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.124N	P=0.158N	P=0.158N	P=0.158N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Skin
 Fibroma, Fibrosarcoma, Sarcoma, Myxoma, Myxosarcoma, or Fibrous Histiocytoma**

TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	1/50 (2%)	3/50 (6%)	0/50 (0%)
POLY-3 RATE (b)	1/43.63	1/48.36	3/45.66	0/45.17
POLY-3 PERCENT (g)	2.3%	2.1%	6.6%	0%
TERMINAL (d)	0/36 (0%)	1/44 (2%)	1/34 (3%)	0/37 (0%)
FIRST INCIDENCE	636	729 (T)	256	---
HC TUMORS SAME RTE	1/50 (2%)			
HC TUMORS ALL RTES	14/1149 (1%)			

STATISTICAL TESTS

POLY 3	P=0.359N	P=0.737N	P=0.322	P=0.493N
POLY 1.5	P=0.358N	P=0.746N	P=0.315	P=0.496N
POLY 6	P=0.360N	P=0.726N	P=0.329	P=0.490N
COCH-ARM / FISHERS	P=0.358N	P=0.753N	P=0.309	P=0.500N
MAX-ISO-POLY-3	P=0.249N	P=0.471N	P=0.171	P=0.158N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG
Skin				
Fibrosarcoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/43.3	0/48.36	1/44.32	0/45.17
POLY-3 PERCENT (g)	0%	0%	2.3%	0%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	1/34 (3%)	0/37 (0%)
FIRST INCIDENCE	---	---	729 (T)	---
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	0/1149 (0%)			

STATISTICAL TESTS

POLY 3	P=0.790N	(e)	P=0.505	(e)
POLY 1.5	P=0.789N	(e)	P=0.502	(e)
POLY 6	P=0.790N	(e)	P=0.508	(e)
COCH-ARM / FISHERS	P=0.789	(e)	P=0.500	(e)
MAX-ISO-POLY-3	P=0.399	(e)	P=0.164	(e)
HISTCONT SAME RTE	(h)	(e)	(h)	(e)
HISTCONT ALL RTES	(h)	(e)	(h)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Skin
 Fibrosarcoma, Sarcoma, Myxosarcoma, or Fibrous Histiocytoma**

TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	0/50 (0%)	3/50 (6%)	0/50 (0%)
POLY-3 RATE (b)	1/43.63	0/48.36	3/45.66	0/45.17
POLY-3 PERCENT (g)	2.3%	0%	6.6%	0%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	1/34 (3%)	0/37 (0%)
FIRST INCIDENCE	636	---	256	---
HC TUMORS SAME RTE	1/50 (2%)			
HC TUMORS ALL RTES	11/1149 (1%)			

STATISTICAL TESTS

POLY 3	P=0.454N	P=0.480N	P=0.322	P=0.493N
POLY 1.5	P=0.451N	P=0.488N	P=0.315	P=0.496N
POLY 6	P=0.459N	P=0.471N	P=0.329	P=0.490N
COCH-ARM / FISHERS	P=0.446N	P=0.500N	P=0.309	P=0.500N
MAX-ISO-POLY-3	P=0.292N	P=0.158N	P=0.171	P=0.158N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG
Skin				
Hemangiosarcoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	2/50 (4%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	1/43.3	2/48.36	1/44.43	0/45.17
POLY-3 PERCENT (g)	2.3%	4.1%	2.3%	0%
TERMINAL (d)	1/36 (3%)	2/44 (5%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	701	---
HC TUMORS SAME RTE	1/50 (2%)			
HC TUMORS ALL RTES	7/1149 (1%)			

STATISTICAL TESTS

POLY 3	P=0.243N	P=0.538	P=0.755N	P=0.492N
POLY 1.5	P=0.246N	P=0.523	P=0.758N	P=0.495N
POLY 6	P=0.240N	P=0.556	P=0.750N	P=0.487N
COCH-ARM / FISHERS	P=0.250N	P=0.500	P=0.753N	P=0.500N
MAX-ISO-POLY-3	P=0.252N	P=0.322	P=0.492N	P=0.158N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG
Skin				
Liposarcoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.3	0/48.36	0/44.32	0/45.17
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	0/1149 (0%)			

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Spleen
 Hemangiosarcoma**

TUMOR RATES

OVERALL (a)	1/50 (2%)	1/50 (2%)	5/50 (10%)	1/50 (2%)
POLY-3 RATE (b)	1/43.3	1/48.36	5/44.61	1/45.17
POLY-3 PERCENT (g)	2.3%	2.1%	11.2%	2.2%
TERMINAL (d)	1/36 (3%)	1/44 (2%)	3/34 (9%)	1/37 (3%)
FIRST INCIDENCE	729 (T)	729 (T)	683	729 (T)
HC TUMORS SAME RTE	2/49 (4%)			
HC TUMORS ALL RTES	21/1136 (2%)			

STATISTICAL TESTS

POLY 3	P=0.614N	P=0.735N	P=0.108	P=0.751N
POLY 1.5	P=0.614N	P=0.746N	P=0.104	P=0.755N
POLY 6	P=0.614N	P=0.723N	P=0.113	P=0.746N
COCH-ARM / FISHERS	P=0.614	P=0.753N	P=0.102	P=0.753N
MAX-ISO-POLY-3	P=0.254	P=0.469N	P=0.050*	P=0.487N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Stomach, Forestomach
 Squamous Cell Carcinoma or Papilloma Squamous**

TUMOR RATES	#	#	#	#
OVERALL (a)	2/50 (4%)	0/50 (0%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	2/43.95	0/48.36	2/44.67	1/45.17
POLY-3 PERCENT (g)	4.6%	0%	4.5%	2.2%
TERMINAL (d)	1/36 (3%)	0/44 (0%)	1/34 (3%)	1/37 (3%)
FIRST INCIDENCE	513	---	631	729 (T)
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	13/1149 (1%)			

STATISTICAL TESTS

POLY 3	P=0.563N	P=0.217N	P=0.688N	P=0.490N
POLY 1.5	P=0.557N	P=0.225N	P=0.693N	P=0.494N
POLY 6	P=0.570N	P=0.207N	P=0.682N	P=0.485N
COCH-ARM / FISHERS	P=0.548N	P=0.247N	P=0.691N	P=0.500N
MAX-ISO-POLY-3	P=0.406N	P=0.076N	P=0.493N	P=0.275N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Stomach, Forestomach
 Squamous Cell Papilloma**

TUMOR RATES	#	#	#	#
OVERALL (a)	2/50 (4%)	0/50 (0%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	2/43.95	0/48.36	1/44.32	1/45.17
POLY-3 PERCENT (g)	4.6%	0%	2.3%	2.2%
TERMINAL (d)	1/36 (3%)	0/44 (0%)	1/34 (3%)	1/37 (3%)
FIRST INCIDENCE	513	---	729 (T)	729 (T)
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	11/1149 (1%)			

STATISTICAL TESTS

POLY 3	P=0.569N	P=0.217N	P=0.497N	P=0.490N
POLY 1.5	P=0.563N	P=0.225N	P=0.500N	P=0.494N
POLY 6	P=0.577N	P=0.207N	P=0.493N	P=0.485N
COCH-ARM / FISHERS	P=0.554N	P=0.247N	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.267N	P=0.076N	P=0.279N	P=0.275N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Thyroid Gland: Follicular Cell
 Carcinoma or Adenoma**

TUMOR RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/43.3	0/48.36	1/44.32	0/45.17
POLY-3 PERCENT (g)	0%	0%	2.3%	0%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	1/34 (3%)	0/37 (0%)
FIRST INCIDENCE	---	---	729 (T)	---
HC TUMORS SAME RTE	3/50 (6%)			
HC TUMORS ALL RTES	22/1142 (2%)			

STATISTICAL TESTS

POLY 3	P=0.790N	(e)	P=0.505	(e)
POLY 1.5	P=0.789N	(e)	P=0.502	(e)
POLY 6	P=0.790N	(e)	P=0.508	(e)
COCH-ARM / FISHERS	P=0.789	(e)	P=0.500	(e)
MAX-ISO-POLY-3	P=0.399	(e)	P=0.164	(e)
HISTCONT SAME RTE	(h)	(e)	(h)	(e)
HISTCONT ALL RTES	(h)	(e)	(h)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG
All Organs				
Hemangioma				
TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	0/50 (0%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	1/43.3	0/48.36	1/44.32	1/45.17
POLY-3 PERCENT (g)	2.3%	0%	2.3%	2.2%
TERMINAL (d)	1/36 (3%)	0/44 (0%)	1/34 (3%)	1/37 (3%)
FIRST INCIDENCE	729 (T)	---	729 (T)	729 (T)
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	9/1149 (1%)			

STATISTICAL TESTS

POLY 3	P=0.553	P=0.478N	P=0.756N	P=0.751N
POLY 1.5	P=0.557	P=0.487N	P=0.759N	P=0.755N
POLY 6	P=0.549	P=0.468N	P=0.752N	P=0.746N
COCH-ARM / FISHERS	P=0.562	P=0.500N	P=0.753N	P=0.753N
MAX-ISO-POLY-3	P=0.542	P=0.158N	P=0.493N	P=0.487N
HISTCONT SAME RTE	P=0.278	(e)	P=0.212	P=0.218
HISTCONT ALL RTES	P=0.408	(e)	P=0.277	P=0.280

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**All Organs
 Hemangiosarcoma**

TUMOR RATES	#	#	#	#
OVERALL (a)	5/50 (10%)	4/50 (8%)	8/50 (16%)	5/50 (10%)
POLY-3 RATE (b)	5/43.71	4/48.36	8/44.62	5/45.32
POLY-3 PERCENT (g)	11.4%	8.3%	17.9%	11%
TERMINAL (d)	4/36 (11%)	4/44 (9%)	5/34 (15%)	4/37 (11%)
FIRST INCIDENCE	610	729 (T)	683	690
HC TUMORS SAME RTE	6/50 (12%)			
HC TUMORS ALL RTES	67/1149 (6%)			

STATISTICAL TESTS

POLY 3	P=0.520	P=0.437N	P=0.288	P=0.608N
POLY 1.5	P=0.522	P=0.462N	P=0.279	P=0.617N
POLY 6	P=0.519	P=0.410N	P=0.299	P=0.596N
COCH-ARM / FISHERS	P=0.524	P=0.500N	P=0.277	P=0.630N
MAX-ISO-POLY-3	P=0.412	P=0.315N	P=0.198	P=0.475N
HISTCONT SAME RTE	P=0.537	P=1.000	P=0.311	P=1.000
HISTCONT ALL RTES	P=0.100	P=0.465	P=0.050*	P=0.275

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**All Organs
 Hemangiosarcoma or Hemangioma**

TUMOR RATES	#	#	#	#
OVERALL (a)	5/50 (10%)	4/50 (8%)	9/50 (18%)	6/50 (12%)
POLY-3 RATE (b)	5/43.71	4/48.36	9/44.62	6/45.32
POLY-3 PERCENT (g)	11.4%	8.3%	20.2%	13.2%
TERMINAL (d)	4/36 (11%)	4/44 (9%)	6/34 (18%)	5/37 (14%)
FIRST INCIDENCE	610	729 (T)	683	690
HC TUMORS SAME RTE	6/50 (12%)			
HC TUMORS ALL RTES	76/1149 (7%)			

STATISTICAL TESTS

POLY 3	P=0.381	P=0.437N	P=0.202	P=0.525
POLY 1.5	P=0.383	P=0.462N	P=0.195	P=0.515
POLY 6	P=0.378	P=0.410N	P=0.212	P=0.538
COCH-ARM / FISHERS	P=0.386	P=0.500N	P=0.194	P=0.500
MAX-ISO-POLY-3	P=0.282	P=0.315N	P=0.133	P=0.398
HISTCONT SAME RTE	P=0.409	P=1.000	P=0.218	P=0.564
HISTCONT ALL RTES	P=0.046*	P=0.531	P=0.028*	P=0.180

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**All Organs
 Histiocytic Sarcoma**

TUMOR RATES

	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/43.3	0/48.36	1/44.33	0/45.17
POLY-3 PERCENT (g)	0%	0%	2.3%	0%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	725	---
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	7/1149 (1%)			

STATISTICAL TESTS

POLY 3	P=0.790N	(e)	P=0.505	(e)
POLY 1.5	P=0.789N	(e)	P=0.502	(e)
POLY 6	P=0.790N	(e)	P=0.508	(e)
COCH-ARM / FISHERS	P=0.789	(e)	P=0.500	(e)
MAX-ISO-POLY-3	P=0.399	(e)	P=0.164	(e)
HISTCONT SAME RTE	(h)	(e)	(h)	(e)
HISTCONT ALL RTES	(h)	(e)	(h)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**All Organs
 Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed, NOS, or Undifferentiated Cell Type**

TUMOR RATES	#	#	#	#
OVERALL (a)	4/50 (8%)	6/50 (12%)	3/50 (6%)	6/50 (12%)
POLY-3 RATE (b)	4/43.48	6/48.36	3/44.32	6/46.52
POLY-3 PERCENT (g)	9.2%	12.4%	6.8%	12.9%
TERMINAL (d)	3/36 (8%)	6/44 (14%)	3/34 (9%)	1/37 (3%)
FIRST INCIDENCE	682	729 (T)	729 (T)	526
HC TUMORS SAME RTE	2/50 (4%)			
HC TUMORS ALL RTES	34/1149 (3%)			

STATISTICAL TESTS

POLY 3	P=0.399	P=0.438	P=0.490N	P=0.413
POLY 1.5	P=0.389	P=0.411	P=0.497N	P=0.395
POLY 6	P=0.414	P=0.469	P=0.482N	P=0.437
COCH-ARM / FISHERS	P=0.374	P=0.370	P=0.500N	P=0.370
MAX-ISO-POLY-3	P=0.468	P=0.321	P=0.339N	P=0.296
HISTCONT SAME RTE	P=0.144	P=0.151	P=0.424	P=0.143
HISTCONT ALL RTES	P<0.001**	P=0.011*	P=0.192	P=0.011*

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG
All Organs				
Benign Tumors				
TUMOR RATES	#	#	#	#
OVERALL (a)	38/50 (76%)	43/50 (86%)	35/50 (70%)	46/50 (92%)
POLY-3 RATE (b)	38/46.32	43/48.67	35/46.1	46/48.48
POLY-3 PERCENT (g)	82%	88.3%	75.9%	94.9%
TERMINAL (d)	31/36 (86%)	41/44 (93%)	28/34 (82%)	36/37 (97%)
FIRST INCIDENCE	489	652	613	493
HC TUMORS SAME RTE	37/50 (74%)			
HC TUMORS ALL RTES	753/1149 (66%)			

STATISTICAL TESTS

POLY 3	P=0.048*	P=0.269	P=0.312N	P=0.034*
POLY 1.5	P=0.043*	P=0.216	P=0.337N	P=0.028*
POLY 6	P=0.062	P=0.335	P=0.270N	P=0.051
COCH-ARM / FISHERS	P=0.046*	P=0.154	P=0.326N	P=0.027*
MAX-ISO-POLY-3	P=0.047*	P=0.183	P=0.225N	P=0.016*
HISTCONT SAME RTE	P=0.081	P=0.134	P=1.000	P=0.030*
HISTCONT ALL RTES	P=0.018*	P=0.137	P=0.427	P=0.017*

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG
All Organs				
Malignant Tumors				
TUMOR RATES	#	#	#	#
OVERALL (a)	37/50 (74%)	41/50 (82%)	38/50 (76%)	44/50 (88%)
POLY-3 RATE (b)	37/48.79	41/50	38/49.08	44/50
POLY-3 PERCENT (g)	75.8%	82%	77.4%	88%
TERMINAL (d)	25/36 (69%)	35/44 (80%)	23/34 (68%)	31/37 (84%)
FIRST INCIDENCE	398	593	256	485
HC TUMORS SAME RTE	26/50 (52%)			
HC TUMORS ALL RTES	582/1149 (51%)			

STATISTICAL TESTS

POLY 3	P=0.095	P=0.306	P=0.521	P=0.092
POLY 1.5	P=0.084	P=0.277	P=0.502	P=0.078
POLY 6	P=0.108	P=0.340	P=0.551	P=0.109
COCH-ARM / FISHERS	P=0.072	P=0.235	P=0.500	P=0.062
MAX-ISO-POLY-3	P=0.100	P=0.229	P=0.425	P=0.057
HISTCONT SAME RTE	P=0.074	P=0.148	P=0.181	P=0.099
HISTCONT ALL RTES	P<0.001**	P=0.033*	P=0.060	P=0.018*

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**All Organs
 Malignant and Benign Tumors**

TUMOR RATES	#	#	#	#
OVERALL (a)	47/50 (94%)	50/50 (100%)	44/50 (88%)	50/50 (100%)
POLY-3 RATE (b)	47/49.44	50/50	44/49.08	50/50
POLY-3 PERCENT (g)	95.1%	100%	89.6%	100%
TERMINAL (d)	34/36 (94%)	44/44 (100%)	29/34 (85%)	37/37 (100%)
FIRST INCIDENCE	398	593	256	485
HC TUMORS SAME RTE	46/50 (92%)			
HC TUMORS ALL RTES	976/1149 (85%)			

STATISTICAL TESTS

POLY 3	P=0.240	P=0.159	P=0.260N	P=0.159
POLY 1.5	P=0.218	P=0.138	P=0.266N	P=0.138
POLY 6	P=0.269	P=0.194	P=0.239N	P=0.194
COCH-ARM / FISHERS	P=0.206	P=0.121	P=0.243N	P=0.121
MAX-ISO-POLY-3	P=0.136	P=0.047*	P=0.153N	P=0.047*
HISTCONT SAME RTE	P=0.215	P=0.082	P=1.000	P=0.082
HISTCONT ALL RTES	P=0.063	P=0.051	P=0.468	P=0.051

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Adrenal Cortex
 Adenoma**

TUMOR RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.96	0/45.74	0/44.97	0/45.74
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	0/40 (0%)	0/40 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	5/1244 (0%)			

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
Harderian Gland Adenoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	9/50 (18%)	5/50 (10%)	11/50 (22%)	4/50 (8%)
POLY-3 RATE (b)	9/44.34	5/45.74	11/46.27	4/45.74
POLY-3 PERCENT (g)	20.3%	10.9%	23.8%	8.8%
TERMINAL (d)	8/35 (23%)	5/40 (13%)	9/40 (23%)	4/40 (10%)
FIRST INCIDENCE	622	729 (T)	508	729 (T)
HC TUMORS SAME RTE	4/50 (8%)			
HC TUMORS ALL RTES	128/1249 (10%)			

STATISTICAL TESTS

POLY 3	P=0.129N	P=0.174N	P=0.442	P=0.103N
POLY 1.5	P=0.135N	P=0.180N	P=0.424	P=0.109N
POLY 6	P=0.121N	P=0.167N	P=0.465	P=0.094N
COCH-ARM / FISHERS	P=0.139N	P=0.194N	P=0.402	P=0.117N
MAX-ISO-POLY-3	P=0.115N	P=0.113N	P=0.348	P=0.061N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
Harderian Gland Carcinoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	1/50 (2%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	1/44.49	1/45.74	1/44.97	2/45.78
POLY-3 PERCENT (g)	2.3%	2.2%	2.2%	4.4%
TERMINAL (d)	0/35 (0%)	1/40 (3%)	1/40 (3%)	1/40 (3%)
FIRST INCIDENCE	565	729 (T)	729 (T)	718
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	33/1249 (3%)			

STATISTICAL TESTS

POLY 3	P=0.380	P=0.754N	P=0.758N	P=0.510
POLY 1.5	P=0.376	P=0.756N	P=0.760N	P=0.505
POLY 6	P=0.386	P=0.752N	P=0.756N	P=0.518
COCH-ARM / FISHERS	P=0.373	P=0.753N	P=0.753N	P=0.500
MAX-ISO-POLY-3	P=0.439	P=0.491N	P=0.496N	P=0.292
HISTCONT SAME RTE	P=0.068	P=0.216	P=0.210	P=0.138
HISTCONT ALL RTES	P=0.513	P=1.000	P=1.000	P=0.364

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Harderian Gland
 Carcinoma or Adenoma**

TUMOR RATES

	#	#	#	#
OVERALL (a)	10/50 (20%)	6/50 (12%)	12/50 (24%)	6/50 (12%)
POLY-3 RATE (b)	10/44.87	6/45.74	12/46.27	6/45.78
POLY-3 PERCENT (g)	22.3%	13.1%	25.9%	13.1%
TERMINAL (d)	8/35 (23%)	6/40 (15%)	10/40 (25%)	5/40 (13%)
FIRST INCIDENCE	565	729 (T)	508	718
HC TUMORS SAME RTE	4/50 (8%)			
HC TUMORS ALL RTES	160/1249 (13%)			

STATISTICAL TESTS

POLY 3	P=0.234N	P=0.192N	P=0.436	P=0.192N
POLY 1.5	P=0.241N	P=0.196N	P=0.422	P=0.199N
POLY 6	P=0.223N	P=0.187N	P=0.452	P=0.181N
COCH-ARM / FISHERS	P=0.243N	P=0.207N	P=0.405	P=0.207N
MAX-ISO-POLY-3	P=0.220N	P=0.128N	P=0.344	P=0.128N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Intestine Small: Jejunum
 Carcinoma**

TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.96	0/45.74	0/44.97	0/45.74
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	0/40 (0%)	0/40 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	4/1249 (0%)			

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Intestine Small: Site Unspecified
 Carcinoma**

TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.96	0/45.74	0/44.97	0/45.74
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	0/40 (0%)	0/40 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME RTE	1/50 (2%)			
HC TUMORS ALL RTES	6/1249 (1%)			

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Islets, Pancreatic
 Adenoma**

TUMOR RATES

OVERALL (a)	0/49 (0%)	2/50 (4%)	4/49 (8%)	4/48 (8%)
POLY-3 RATE (b)	0/43.53	2/45.74	4/44.63	4/44.84
POLY-3 PERCENT (g)	0%	4.4%	9%	8.9%
TERMINAL (d)	0/35 (0%)	2/40 (5%)	4/40 (10%)	3/40 (8%)
FIRST INCIDENCE	---	729 (T)	729 (T)	654
HC TUMORS SAME RTE	1/46 (2%)			
HC TUMORS ALL RTES	12/1228 (1%)			

STATISTICAL TESTS

POLY 3	P=0.137	P=0.248	P=0.063	P=0.064
POLY 1.5	P=0.130	P=0.246	P=0.062	P=0.061
POLY 6	P=0.147	P=0.251	P=0.065	P=0.068
COCH-ARM / FISHERS	P=0.125	P=0.253	P=0.059	P=0.056
MAX-ISO-POLY-3	P=0.060	P=0.086	P=0.022*	P=0.023*
HISTCONT SAME RTE	P=0.099	P=0.145	P=0.039*	P=0.041*
HISTCONT ALL RTES	P=0.002**	P=0.088	P=0.004**	P=0.004**

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

Liver
 Hemangiosarcoma

TUMOR RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	0/43.96	1/46.12	1/44.97	1/46.55
POLY-3 PERCENT (g)	0%	2.2%	2.2%	2.2%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	1/40 (3%)	0/40 (0%)
FIRST INCIDENCE	---	622	729 (T)	420
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	11/1245 (1%)			

STATISTICAL TESTS

POLY 3	P=0.567	P=0.510	P=0.505	P=0.511
POLY 1.5	P=0.560	P=0.506	P=0.502	P=0.506
POLY 6	P=0.576	P=0.514	P=0.508	P=0.518
COCH-ARM / FISHERS	P=0.551	P=0.500	P=0.500	P=0.500
MAX-ISO-POLY-3	P=0.355	P=0.171	P=0.164	P=0.173
HISTCONT SAME RTE	P=0.281	P=0.213	P=0.207	P=0.215
HISTCONT ALL RTES	P=0.411	P=0.203	P=0.195	P=0.206

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
Liver				
Hepatoblastoma				
TUMOR RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.96	0/45.74	0/44.97	0/45.74
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	0/40 (0%)	0/40 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	6/1245 (1%)			
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

Liver
 Hepatocellular Adenoma

TUMOR RATES

OVERALL (a)	14/50 (28%)	16/50 (32%)	18/50 (36%)	28/50 (56%)
POLY-3 RATE (b)	14/44.34	16/46.27	18/46.08	28/45.82
POLY-3 PERCENT (g)	31.6%	34.6%	39.1%	61.1%
TERMINAL (d)	13/35 (37%)	14/40 (35%)	16/40 (40%)	27/40 (68%)
FIRST INCIDENCE	622	622	520	708
HC TUMORS SAME RTE	15/50 (30%)			
HC TUMORS ALL RTEs	345/1245 (28%)			

STATISTICAL TESTS

POLY 3	P<0.001**	P=0.468	P=0.299	P=0.003**
POLY 1.5	P<0.001**	P=0.449	P=0.280	P=0.003**
POLY 6	P<0.001**	P=0.497	P=0.326	P=0.004**
COCH-ARM / FISHERS	P<0.001**	P=0.414	P=0.260	P=0.004**
MAX-ISO-POLY-3	P=0.002**	P=0.382	P=0.232	P=0.002**
HISTCONT SAME RTE	P=0.003**	P=0.362	P=0.252	P=0.004**
HISTCONT ALL RTEs	P=0.002**	P=0.483	P=0.283	P=0.002**

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Liver
 Hepatocellular Carcinoma**

TUMOR RATES

OVERALL (a)	5/50 (10%)	13/50 (26%)	15/50 (30%)	15/50 (30%)
POLY-3 RATE (b)	5/44.13	13/46.06	15/46.91	15/45.87
POLY-3 PERCENT (g)	11.3%	28.2%	32%	32.7%
TERMINAL (d)	3/35 (9%)	11/40 (28%)	11/40 (28%)	13/40 (33%)
FIRST INCIDENCE	687	685	442	708
HC TUMORS SAME RTE	5/50 (10%)			
HC TUMORS ALL RTES	131/1245 (11%)			

STATISTICAL TESTS

POLY 3	P=0.098	P=0.038*	P=0.015*	P=0.012*
POLY 1.5	P=0.093	P=0.036*	P=0.013*	P=0.011*
POLY 6	P=0.108	P=0.042*	P=0.018*	P=0.014*
COCH-ARM / FISHERS	P=0.093	P=0.033*	P=0.011*	P=0.011*
MAX-ISO-POLY-3	P=0.019*	P=0.023*	P=0.009**	P=0.007**
HISTCONT SAME RTE	P=0.033*	P=0.042*	P=0.017*	P=0.013*
HISTCONT ALL RTES	P=0.015*	P=0.024*	P=0.009**	P=0.007**

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Liver
 Hepatocellular Carcinoma or Hepatoblastoma**

TUMOR RATES

OVERALL (a)	5/50 (10%)	13/50 (26%)	15/50 (30%)	15/50 (30%)
POLY-3 RATE (b)	5/44.13	13/46.06	15/46.91	15/45.87
POLY-3 PERCENT (g)	11.3%	28.2%	32%	32.7%
TERMINAL (d)	3/35 (9%)	11/40 (28%)	11/40 (28%)	13/40 (33%)
FIRST INCIDENCE	687	685	442	708
HC TUMORS SAME RTE	5/50 (10%)			
HC TUMORS ALL RTES	136/1245 (11%)			

STATISTICAL TESTS

POLY 3	P=0.098	P=0.038*	P=0.015*	P=0.012*
POLY 1.5	P=0.093	P=0.036*	P=0.013*	P=0.011*
POLY 6	P=0.108	P=0.042*	P=0.018*	P=0.014*
COCH-ARM / FISHERS	P=0.093	P=0.033*	P=0.011*	P=0.011*
MAX-ISO-POLY-3	P=0.019*	P=0.023*	P=0.009**	P=0.007**
HISTCONT SAME RTE	P=0.033*	P=0.042*	P=0.017*	P=0.013*
HISTCONT ALL RTES	P=0.018*	P=0.024*	P=0.009**	P=0.007**

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Liver
 Hepatocellular Carcinoma or Hepatocellular Adenoma**

TUMOR RATES

OVERALL (a)	17/50 (34%)	23/50 (46%)	27/50 (54%)	32/50 (64%)
POLY-3 RATE (b)	17/44.51	23/46.44	27/47.39	32/45.87
POLY-3 PERCENT (g)	38.2%	49.5%	57%	69.8%
TERMINAL (d)	14/35 (40%)	20/40 (50%)	22/40 (55%)	30/40 (75%)
FIRST INCIDENCE	622	622	442	708
HC TUMORS SAME RTE	19/50 (38%)			
HC TUMORS ALL RTES	419/1245 (34%)			

STATISTICAL TESTS

POLY 3	P=0.004**	P=0.188	P=0.052	P<0.001**
POLY 1.5	P=0.004**	P=0.175	P=0.042*	P<0.001**
POLY 6	P=0.004**	P=0.209	P=0.067	P=0.002**
COCH-ARM / FISHERS	P=0.006**	P=0.154	P=0.035*	P=0.002**
MAX-ISO-POLY-3	P=0.002**	P=0.141	P=0.037*	P<0.001**
HISTCONT SAME RTE	P=0.004**	P=0.229	P=0.066	P=0.002**
HISTCONT ALL RTES	P=0.002**	P=0.165	P=0.039*	P<0.001**

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

Liver
 Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma

TUMOR RATES

OVERALL (a)	17/50 (34%)	23/50 (46%)	27/50 (54%)	32/50 (64%)
POLY-3 RATE (b)	17/44.51	23/46.44	27/47.39	32/45.87
POLY-3 PERCENT (g)	38.2%	49.5%	57%	69.8%
TERMINAL (d)	14/35 (40%)	20/40 (50%)	22/40 (55%)	30/40 (75%)
FIRST INCIDENCE	622	622	442	708
HC TUMORS SAME RTE	19/50 (38%)			
HC TUMORS ALL RTEs	421/1245 (34%)			

STATISTICAL TESTS

POLY 3	P=0.004**	P=0.188	P=0.052	P<0.001**
POLY 1.5	P=0.004**	P=0.175	P=0.042*	P<0.001**
POLY 6	P=0.004**	P=0.209	P=0.067	P=0.002**
COCH-ARM / FISHERS	P=0.006**	P=0.154	P=0.035*	P=0.002**
MAX-ISO-POLY-3	P=0.002**	P=0.141	P=0.037*	P<0.001**
HISTCONT SAME RTE	P=0.004**	P=0.229	P=0.066	P=0.002**
HISTCONT ALL RTEs	P=0.002**	P=0.165	P=0.039*	P<0.001**

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Lung
 Alveolar/Bronchiolar Adenoma**

TUMOR RATES

OVERALL (a)	0/50 (0%)	2/50 (4%)	3/50 (6%)	0/50 (0%)
POLY-3 RATE (b)	0/43.96	2/45.74	3/44.97	0/45.74
POLY-3 PERCENT (g)	0%	4.4%	6.7%	0%
TERMINAL (d)	0/35 (0%)	2/40 (5%)	3/40 (8%)	0/40 (0%)
FIRST INCIDENCE	---	729 (T)	729 (T)	---
HC TUMORS SAME RTE	1/50 (2%)			
HC TUMORS ALL RTES	65/1248 (5%)			

STATISTICAL TESTS

POLY 3	P=0.286N	P=0.246	P=0.123	(e)
POLY 1.5	P=0.293N	P=0.243	P=0.121	(e)
POLY 6	P=0.276N	P=0.250	P=0.126	(e)
COCH-ARM / FISHERS	P=0.300N	P=0.247	P=0.121	(e)
MAX-ISO-POLY-3	P=0.242N	P=0.085	P=0.041*	(e)
HISTCONT SAME RTE	(h)	(h)	(h)	(e)
HISTCONT ALL RTES	(h)	(h)	(h)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Lung
 Alveolar/Bronchiolar Carcinoma**

TUMOR RATES

OVERALL (a)	4/50 (8%)	3/50 (6%)	0/50 (0%)	5/50 (10%)
POLY-3 RATE (b)	4/44.13	3/46.41	0/44.97	5/46.48
POLY-3 PERCENT (g)	9.1%	6.5%	0%	10.8%
TERMINAL (d)	3/35 (9%)	2/40 (5%)	0/40 (0%)	4/40 (10%)
FIRST INCIDENCE	684	502	---	463
HC TUMORS SAME RTE	5/50 (10%)			
HC TUMORS ALL RTES	47/1248 (4%)			

STATISTICAL TESTS

POLY 3	P=0.240	P=0.473N	P=0.058N	P=0.532
POLY 1.5	P=0.235	P=0.482N	P=0.059N	P=0.518
POLY 6	P=0.246	P=0.461N	P=0.056N	P=0.550
COCH-ARM / FISHERS	P=0.231	P=0.500N	P=0.059N	P=0.500
MAX-ISO-POLY-3	P=0.244	P=0.327N	P=0.019N*	P=0.395
HISTCONT SAME RTE	P=0.358	P=1.000	(e)	P=0.560
HISTCONT ALL RTES	P=0.187	P=0.410	(e)	P=0.126

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

Lung
Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma

TUMOR RATES

OVERALL (a)	4/50 (8%)	5/50 (10%)	3/50 (6%)	5/50 (10%)
POLY-3 RATE (b)	4/44.13	5/46.41	3/44.97	5/46.48
POLY-3 PERCENT (g)	9.1%	10.8%	6.7%	10.8%
TERMINAL (d)	3/35 (9%)	4/40 (10%)	3/40 (8%)	4/40 (10%)
FIRST INCIDENCE	684	502	729 (T)	463
HC TUMORS SAME RTE	6/50 (12%)			
HC TUMORS ALL RTES	107/1248 (9%)			

STATISTICAL TESTS

POLY 3	P=0.490	P=0.531	P=0.490N	P=0.532
POLY 1.5	P=0.479	P=0.521	P=0.495N	P=0.518
POLY 6	P=0.503	P=0.544	P=0.482N	P=0.550
COCH-ARM / FISHERS	P=0.468	P=0.500	P=0.500N	P=0.500
MAX-ISO-POLY-3	P=0.599	P=0.394	P=0.339N	P=0.395
HISTCONT SAME RTE	P=0.745	P=0.560	P=1.000	P=0.560
HISTCONT ALL RTES	P=0.705	P=0.501	P=1.000	P=0.502

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
Mammary Gland Carcinoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/43.96	2/45.74	0/44.97	0/45.74
POLY-3 PERCENT (g)	2.3%	4.4%	0%	0%
TERMINAL (d)	1/35 (3%)	2/40 (5%)	0/40 (0%)	0/40 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	---	---
HC TUMORS SAME RTE	2/50 (4%)			
HC TUMORS ALL RTES	16/1249 (1%)			

STATISTICAL TESTS

POLY 3	P=0.253N	P=0.514	P=0.495N	P=0.492N
POLY 1.5	P=0.256N	P=0.509	P=0.498N	P=0.496N
POLY 6	P=0.250N	P=0.520	P=0.492N	P=0.487N
COCH-ARM / FISHERS	P=0.259N	P=0.500	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.187N	P=0.296	P=0.158N	P=0.158N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
Mammary Gland Carcinoma or Adenoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	3/50 (6%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/43.96	3/45.92	0/44.97	0/45.74
POLY-3 PERCENT (g)	2.3%	6.5%	0%	0%
TERMINAL (d)	1/35 (3%)	2/40 (5%)	0/40 (0%)	0/40 (0%)
FIRST INCIDENCE	729 (T)	681	---	---
HC TUMORS SAME RTE	2/50 (4%)			
HC TUMORS ALL RTES	16/1249 (1%)			

STATISTICAL TESTS

POLY 3	P=0.176N	P=0.321	P=0.495N	P=0.492N
POLY 1.5	P=0.179N	P=0.316	P=0.498N	P=0.496N
POLY 6	P=0.172N	P=0.329	P=0.492N	P=0.487N
COCH-ARM / FISHERS	P=0.185N	P=0.309	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.132N	P=0.171	P=0.158N	P=0.158N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Mammary Gland
 Fibroma, Fibroadenoma, Carcinoma, or Adenoma**

TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	3/50 (6%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/43.96	3/45.92	0/44.97	0/45.74
POLY-3 PERCENT (g)	2.3%	6.5%	0%	0%
TERMINAL (d)	1/35 (3%)	2/40 (5%)	0/40 (0%)	0/40 (0%)
FIRST INCIDENCE	729 (T)	681	---	---
HC TUMORS SAME RTE	2/50 (4%)			
HC TUMORS ALL RTES	16/1249 (1%)			

STATISTICAL TESTS

POLY 3	P=0.176N	P=0.321	P=0.495N	P=0.492N
POLY 1.5	P=0.179N	P=0.316	P=0.498N	P=0.496N
POLY 6	P=0.172N	P=0.329	P=0.492N	P=0.487N
COCH-ARM / FISHERS	P=0.185N	P=0.309	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.132N	P=0.171	P=0.158N	P=0.158N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Ovary
 Cystadenoma**

TUMOR RATES

OVERALL (a)	4/49 (8%)	3/50 (6%)	2/49 (4%)	2/48 (4%)
POLY-3 RATE (b)	4/42.96	3/45.74	2/44.23	2/44.48
POLY-3 PERCENT (g)	9.3%	6.6%	4.5%	4.5%
TERMINAL (d)	4/34 (12%)	3/40 (8%)	1/39 (3%)	2/39 (5%)
FIRST INCIDENCE	729 (T)	729 (T)	659	729 (T)
HC TUMORS SAME RTE	2/47 (4%)			
HC TUMORS ALL RTES	46/1221 (4%)			

STATISTICAL TESTS

POLY 3	P=0.355N	P=0.466N	P=0.323N	P=0.321N
POLY 1.5	P=0.362N	P=0.474N	P=0.331N	P=0.333N
POLY 6	P=0.346N	P=0.455N	P=0.313N	P=0.306N
COCH-ARM / FISHERS	P=0.368N	P=0.489N	P=0.339N	P=0.349N
MAX-ISO-POLY-3	P=0.300N	P=0.321N	P=0.193N	P=0.193N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Pituitary Gland: Pars Distalis or Unspecified Site
 Adenoma**

TUMOR RATES

OVERALL (a)	1/49 (2%)	2/47 (4%)	4/50 (8%)	4/50 (8%)
POLY-3 RATE (b)	1/43.38	2/43.71	4/44.97	4/45.74
POLY-3 PERCENT (g)	2.3%	4.6%	8.9%	8.8%
TERMINAL (d)	0/35 (0%)	2/39 (5%)	4/40 (10%)	4/40 (10%)
FIRST INCIDENCE	659	729 (T)	729 (T)	729 (T)
HC TUMORS SAME RTE	1/46 (2%)			
HC TUMORS ALL RTES	97/1216 (8%)			

STATISTICAL TESTS

POLY 3	P=0.228	P=0.503	P=0.189	P=0.195
POLY 1.5	P=0.224	P=0.497	P=0.187	P=0.190
POLY 6	P=0.234	P=0.510	P=0.192	P=0.201
COCH-ARM / FISHERS	P=0.222	P=0.484	P=0.187	P=0.187
MAX-ISO-POLY-3	P=0.178	P=0.286	P=0.093	P=0.098
HISTCONT SAME RTE	P=0.251	P=0.233	P=0.157	P=0.164
HISTCONT ALL RTES	P=0.204	P=0.356	P=0.106	P=0.113

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
Skeletal Muscle Sarcoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/43.96	0/45.74	2/44.97	0/45.74
POLY-3 PERCENT (g)	0%	0%	4.5%	0%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	2/40 (5%)	0/40 (0%)
FIRST INCIDENCE	---	---	729 (T)	---
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	3/1249 (0%)			

STATISTICAL TESTS

POLY 3	P=0.618N	(e)	P=0.242	(e)
POLY 1.5	P=0.622N	(e)	P=0.240	(e)
POLY 6	P=0.612N	(e)	P=0.246	(e)
COCH-ARM / FISHERS	P=0.624N	(e)	P=0.247	(e)
MAX-ISO-POLY-3	P=0.270	(e)	P=0.081	(e)
HISTCONT SAME RTE	(h)	(e)	(h)	(e)
HISTCONT ALL RTES	(h)	(e)	(h)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Skin
 Fibroma, Fibrosarcoma, Sarcoma, Myxoma, Myxosarcoma, or Fibrous Histiocytoma**

TUMOR RATES	#	#	#	#
OVERALL (a)	5/50 (10%)	1/50 (2%)	3/50 (6%)	2/50 (4%)
POLY-3 RATE (b)	5/44.83	1/45.74	3/45.53	2/45.74
POLY-3 PERCENT (g)	11.2%	2.2%	6.6%	4.4%
TERMINAL (d)	1/35 (3%)	1/40 (3%)	1/40 (3%)	2/40 (5%)
FIRST INCIDENCE	659	729 (T)	646	729 (T)
HC TUMORS SAME RTE	3/50 (6%)			
HC TUMORS ALL RTES	53/1249 (4%)			

STATISTICAL TESTS

POLY 3	P=0.387N	P=0.097N	P=0.348N	P=0.208N
POLY 1.5	P=0.390N	P=0.098N	P=0.352N	P=0.212N
POLY 6	P=0.383N	P=0.096N	P=0.342N	P=0.203N
COCH-ARM / FISHERS	P=0.389N	P=0.102N	P=0.357N	P=0.218N
MAX-ISO-POLY-3	P=0.150N	P=0.043N*	P=0.226N	P=0.116N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
Skin				
Fibrosarcoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	3/50 (6%)	0/50 (0%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	3/44.66	0/45.74	2/45.27	1/45.74
POLY-3 PERCENT (g)	6.7%	0%	4.4%	2.2%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	1/40 (3%)	1/40 (3%)
FIRST INCIDENCE	659	---	646	729 (T)
HC TUMORS SAME RTE	3/50 (6%)			
HC TUMORS ALL RTES	20/1249 (2%)			

STATISTICAL TESTS

POLY 3	P=0.475N	P=0.114N	P=0.494N	P=0.297N
POLY 1.5	P=0.477N	P=0.116N	P=0.497N	P=0.301N
POLY 6	P=0.472N	P=0.113N	P=0.490N	P=0.292N
COCH-ARM / FISHERS	P=0.476N	P=0.121N	P=0.500N	P=0.309N
MAX-ISO-POLY-3	P=0.194N	P=0.038N*	P=0.319N	P=0.151N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Skin
 Fibrosarcoma, Sarcoma, Myxosarcoma, or Fibrous Histiocytoma**

TUMOR RATES	#	#	#	#
OVERALL (a)	5/50 (10%)	1/50 (2%)	3/50 (6%)	2/50 (4%)
POLY-3 RATE (b)	5/44.83	1/45.74	3/45.53	2/45.74
POLY-3 PERCENT (g)	11.2%	2.2%	6.6%	4.4%
TERMINAL (d)	1/35 (3%)	1/40 (3%)	1/40 (3%)	2/40 (5%)
FIRST INCIDENCE	659	729 (T)	646	729 (T)
HC TUMORS SAME RTE	3/50 (6%)			
HC TUMORS ALL RTES	53/1249 (4%)			

STATISTICAL TESTS

POLY 3	P=0.387N	P=0.097N	P=0.348N	P=0.208N
POLY 1.5	P=0.390N	P=0.098N	P=0.352N	P=0.212N
POLY 6	P=0.383N	P=0.096N	P=0.342N	P=0.203N
COCH-ARM / FISHERS	P=0.389N	P=0.102N	P=0.357N	P=0.218N
MAX-ISO-POLY-3	P=0.150N	P=0.043N*	P=0.226N	P=0.116N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
Skin				
Hemangiosarcoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	1/43.96	0/45.74	1/45.63	0/45.74
POLY-3 PERCENT (g)	2.3%	0%	2.2%	0%
TERMINAL (d)	1/35 (3%)	0/40 (0%)	0/40 (0%)	0/40 (0%)
FIRST INCIDENCE	729 (T)	---	508	---
HC TUMORS SAME RTE	1/50 (2%)			
HC TUMORS ALL RTES	17/1249 (1%)			

STATISTICAL TESTS

POLY 3	P=0.486N	P=0.492N	P=0.752N	P=0.492N
POLY 1.5	P=0.487N	P=0.495N	P=0.756N	P=0.496N
POLY 6	P=0.484N	P=0.488N	P=0.747N	P=0.487N
COCH-ARM / FISHERS	P=0.486N	P=0.500N	P=0.753N	P=0.500N
MAX-ISO-POLY-3	P=0.261N	P=0.158N	P=0.489N	P=0.158N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
Skin				
Liposarcoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.96	2/46.49	0/44.97	0/45.74
POLY-3 PERCENT (g)	0%	4.3%	0%	0%
TERMINAL (d)	0/35 (0%)	1/40 (3%)	0/40 (0%)	0/40 (0%)
FIRST INCIDENCE	---	456	---	---
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	1/1249 (0%)			

STATISTICAL TESTS

POLY 3	P=0.389N	P=0.250	(e)	(e)
POLY 1.5	P=0.394N	P=0.246	(e)	(e)
POLY 6	P=0.382N	P=0.255	(e)	(e)
COCH-ARM / FISHERS	P=0.403N	P=0.247	(e)	(e)
MAX-ISO-POLY-3	P=0.269N	P=0.088	(e)	(e)
HISTCONT SAME RTE	(h)	(h)	(e)	(e)
HISTCONT ALL RTES	(h)	(h)	(e)	(e)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Spleen
 Hemangiosarcoma**

TUMOR RATES

OVERALL (a)	0/50 (0%)	1/50 (2%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/43.96	1/46.12	0/44.97	1/46.55
POLY-3 PERCENT (g)	0%	2.2%	0%	2.2%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	0/40 (0%)	0/40 (0%)
FIRST INCIDENCE	---	622	---	420
HC TUMORS SAME RTE	0/47 (0%)			
HC TUMORS ALL RTES	24/1230 (2%)			

STATISTICAL TESTS

POLY 3	P=0.500	P=0.510	(e)	P=0.511
POLY 1.5	P=0.494	P=0.506	(e)	P=0.506
POLY 6	P=0.507	P=0.514	(e)	P=0.518
COCH-ARM / FISHERS	P=0.486	P=0.500	(e)	P=0.500
MAX-ISO-POLY-3	P=0.284	P=0.171	(e)	P=0.173
HISTCONT SAME RTE	P=0.286	P=0.221	(e)	P=0.223
HISTCONT ALL RTES	P=0.328	P=0.203	(e)	P=0.206

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Stomach, Forestomach
 Squamous Cell Carcinoma or Papilloma Squamous**

TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	1/43.96	0/45.74	1/44.97	0/45.74
POLY-3 PERCENT (g)	2.3%	0%	2.2%	0%
TERMINAL (d)	1/35 (3%)	0/40 (0%)	1/40 (3%)	0/40 (0%)
FIRST INCIDENCE	729 (T)	---	729 (T)	---
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	22/1249 (2%)			

STATISTICAL TESTS

POLY 3	P=0.485N	P=0.492N	P=0.756N	P=0.492N
POLY 1.5	P=0.487N	P=0.495N	P=0.758N	P=0.496N
POLY 6	P=0.484N	P=0.488N	P=0.752N	P=0.487N
COCH-ARM / FISHERS	P=0.486N	P=0.500N	P=0.753N	P=0.500N
MAX-ISO-POLY-3	P=0.261N	P=0.158N	P=0.493N	P=0.158N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Stomach, Forestomach
 Squamous Cell Papilloma**

TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	1/43.96	0/45.74	1/44.97	0/45.74
POLY-3 PERCENT (g)	2.3%	0%	2.2%	0%
TERMINAL (d)	1/35 (3%)	0/40 (0%)	1/40 (3%)	0/40 (0%)
FIRST INCIDENCE	729 (T)	---	729 (T)	---
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	20/1249 (2%)			

STATISTICAL TESTS

POLY 3	P=0.485N	P=0.492N	P=0.756N	P=0.492N
POLY 1.5	P=0.487N	P=0.495N	P=0.758N	P=0.496N
POLY 6	P=0.484N	P=0.488N	P=0.752N	P=0.487N
COCH-ARM / FISHERS	P=0.486N	P=0.500N	P=0.753N	P=0.500N
MAX-ISO-POLY-3	P=0.261N	P=0.158N	P=0.493N	P=0.158N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Thyroid Gland: Follicular Cell
 Carcinoma or Adenoma**

TUMOR RATES

OVERALL (a)	2/50 (4%)	0/50 (0%)	0/48 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/43.96	0/45.74	0/43.27	0/45.74
POLY-3 PERCENT (g)	4.6%	0%	0%	0%
TERMINAL (d)	2/35 (6%)	0/40 (0%)	0/39 (0%)	0/40 (0%)
FIRST INCIDENCE	729 (T)	---	---	---
HC TUMORS SAME RTE	1/46 (2%)			
HC TUMORS ALL RTES	32/1234 (3%)			

STATISTICAL TESTS

POLY 3	P=0.354N	P=0.228N	P=0.241N	P=0.228N
POLY 1.5	P=0.352N	P=0.231N	P=0.244N	P=0.233N
POLY 6	P=0.356N	P=0.224N	P=0.236N	P=0.222N
COCH-ARM / FISHERS	P=0.349N	P=0.247N	P=0.258N	P=0.247N
MAX-ISO-POLY-3	P=0.037N*	P=0.076N	P=0.078N	P=0.076N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
Uterus				
Polyp Stromal				
TUMOR RATES	#	#	#	#
OVERALL (a)	2/50 (4%)	1/50 (2%)	0/50 (0%)	4/50 (8%)
POLY-3 RATE (b)	2/44.73	1/45.74	0/44.97	4/45.74
POLY-3 PERCENT (g)	4.5%	2.2%	0%	8.8%
TERMINAL (d)	1/35 (3%)	1/40 (3%)	0/40 (0%)	4/40 (10%)
FIRST INCIDENCE	443	729 (T)	---	729 (T)
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	33/1249 (3%)			

STATISTICAL TESTS

POLY 3	P=0.082	P=0.492N	P=0.236N	P=0.347
POLY 1.5	P=0.081	P=0.495N	P=0.237N	P=0.341
POLY 6	P=0.084	P=0.488N	P=0.233N	P=0.358
COCH-ARM / FISHERS	P=0.081	P=0.500N	P=0.247N	P=0.339
MAX-ISO-POLY-3	P=0.091	P=0.276N	P=0.076N	P=0.211
HISTCONT SAME RTE	P=0.126	P=0.421	(e)	P=0.135
HISTCONT ALL RTES	P=0.104	P=1.000	(e)	P=0.088

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
All Organs				
Hemangioma				
TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	1/50 (2%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	1/44.17	1/45.93	0/44.97	2/45.74
POLY-3 PERCENT (g)	2.3%	2.2%	0%	4.4%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	0/40 (0%)	2/40 (5%)
FIRST INCIDENCE	672	680	---	729 (T)
HC TUMORS SAME RTE	1/50 (2%)			
HC TUMORS ALL RTES	20/1249 (2%)			

STATISTICAL TESTS

POLY 3	P=0.314	P=0.752N	P=0.496N	P=0.512
POLY 1.5	P=0.311	P=0.755N	P=0.498N	P=0.506
POLY 6	P=0.318	P=0.748N	P=0.494N	P=0.520
COCH-ARM / FISHERS	P=0.309	P=0.753N	P=0.500N	P=0.500
MAX-ISO-POLY-3	P=0.299	P=0.488N	P=0.158N	P=0.294
HISTCONT SAME RTE	P=0.242	P=1.000	(e)	P=0.205
HISTCONT ALL RTES	P=0.316	P=0.556	(e)	P=0.210

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
All Organs				
Hemangiosarcoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	2/50 (4%)	3/50 (6%)	2/50 (4%)
POLY-3 RATE (b)	1/43.96	2/46.12	3/45.63	2/46.55
POLY-3 PERCENT (g)	2.3%	4.3%	6.6%	4.3%
TERMINAL (d)	1/35 (3%)	1/40 (3%)	2/40 (5%)	1/40 (3%)
FIRST INCIDENCE	729 (T)	622	508	420
HC TUMORS SAME RTE	3/50 (6%)			
HC TUMORS ALL RTES	60/1249 (5%)			

STATISTICAL TESTS

POLY 3	P=0.591	P=0.517	P=0.319	P=0.520
POLY 1.5	P=0.581	P=0.511	P=0.313	P=0.511
POLY 6	P=0.603	P=0.525	P=0.327	P=0.531
COCH-ARM / FISHERS	P=0.571	P=0.500	P=0.309	P=0.500
MAX-ISO-POLY-3	P=0.393	P=0.299	P=0.168	P=0.302
HISTCONT SAME RTE	P=0.538	P=0.443	P=0.269	P=0.448
HISTCONT ALL RTES	P=0.457	P=0.374	P=0.200	P=0.379

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**All Organs
 Hemangiosarcoma or Hemangioma**

TUMOR RATES	#	#	#	#
OVERALL (a)	2/50 (4%)	3/50 (6%)	3/50 (6%)	4/50 (8%)
POLY-3 RATE (b)	2/44.17	3/46.31	3/45.63	4/46.55
POLY-3 PERCENT (g)	4.5%	6.5%	6.6%	8.6%
TERMINAL (d)	1/35 (3%)	1/40 (3%)	2/40 (5%)	3/40 (8%)
FIRST INCIDENCE	672	622	508	420
HC TUMORS SAME RTE	4/50 (8%)			
HC TUMORS ALL RTES	79/1249 (6%)			

STATISTICAL TESTS

POLY 3	P=0.349	P=0.521	P=0.515	P=0.362
POLY 1.5	P=0.340	P=0.514	P=0.508	P=0.351
POLY 6	P=0.358	P=0.532	P=0.523	P=0.374
COCH-ARM / FISHERS	P=0.330	P=0.500	P=0.500	P=0.339
MAX-ISO-POLY-3	P=0.369	P=0.346	P=0.339	P=0.226
HISTCONT SAME RTE	P=0.510	P=0.502	P=0.493	P=0.349
HISTCONT ALL RTES	P=0.429	P=0.437	P=0.427	P=0.276

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
All Organs				
Histiocytic Sarcoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	2/50 (4%)	4/50 (8%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	2/44.17	4/47.78	0/44.97	1/46.02
POLY-3 PERCENT (g)	4.5%	8.4%	0%	2.2%
TERMINAL (d)	1/35 (3%)	1/40 (3%)	0/40 (0%)	0/40 (0%)
FIRST INCIDENCE	672	446	---	654
HC TUMORS SAME RTE	2/50 (4%)			
HC TUMORS ALL RTES	31/1249 (3%)			

STATISTICAL TESTS

POLY 3	P=0.270N	P=0.374	P=0.233N	P=0.486N
POLY 1.5	P=0.275N	P=0.361	P=0.235N	P=0.493N
POLY 6	P=0.263N	P=0.388	P=0.230N	P=0.476N
COCH-ARM / FISHERS	P=0.281N	P=0.339	P=0.247N	P=0.500N
MAX-ISO-POLY-3	P=0.157N	P=0.239	P=0.076N	P=0.272N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**All Organs
 Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed, NOS, or Undifferentiated Cell Type**

TUMOR RATES	#	#	#	#
OVERALL (a)	14/50 (28%)	15/50 (30%)	11/50 (22%)	2/50 (4%)
POLY-3 RATE (b)	14/44.73	15/46.11	11/45.18	2/45.74
POLY-3 PERCENT (g)	31.3%	32.5%	24.4%	4.4%
TERMINAL (d)	11/35 (31%)	13/40 (33%)	10/40 (25%)	2/40 (5%)
FIRST INCIDENCE	547	680	672	729 (T)
HC TUMORS SAME RTE	6/50 (12%)			
HC TUMORS ALL RTES	284/1249 (23%)			

STATISTICAL TESTS

POLY 3	P<0.001N**	P=0.540	P=0.308N	P<0.001N**
POLY 1.5	P<0.001N**	P=0.527	P=0.316N	P<0.001N**
POLY 6	P<0.001N**	P=0.560	P=0.296N	P<0.001N**
COCH-ARM / FISHERS	P<0.001N**	P=0.500	P=0.322N	P<0.001N**
MAX-ISO-POLY-3	P<0.001N**	P=0.449	P=0.232N	P<0.001N**
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
All Organs				
Benign Tumors				
TUMOR RATES	#	#	#	#
OVERALL (a)	27/50 (54%)	27/50 (54%)	31/50 (62%)	32/50 (64%)
POLY-3 RATE (b)	27/45.59	27/46.82	31/47.01	32/46.1
POLY-3 PERCENT (g)	59.2%	57.7%	66%	69.4%
TERMINAL (d)	23/35 (66%)	22/40 (55%)	27/40 (68%)	30/40 (75%)
FIRST INCIDENCE	443	622	508	654
HC TUMORS SAME RTE	25/50 (50%)			
HC TUMORS ALL RTES	644/1249 (52%)			

STATISTICAL TESTS

POLY 3	P=0.151	P=0.524N	P=0.322	P=0.206
POLY 1.5	P=0.153	P=0.544N	P=0.294	P=0.198
POLY 6	P=0.153	P=0.483N	P=0.362	P=0.226
COCH-ARM / FISHERS	P=0.178	P=0.579N	P=0.272	P=0.208
MAX-ISO-POLY-3	P=0.225	P=0.438N	P=0.252	P=0.149
HISTCONT SAME RTE	P=0.106	P=0.287	P=0.130	P=0.134
HISTCONT ALL RTES	P=0.261	P=0.577	P=0.309	P=0.176

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
All Organs				
Malignant Tumors				
TUMOR RATES	#	#	#	#
OVERALL (a)	27/50 (54%)	36/50 (72%)	31/50 (62%)	25/50 (50%)
POLY-3 RATE (b)	27/46.77	36/49.61	31/48.53	25/47.7
POLY-3 PERCENT (g)	57.7%	72.6%	63.9%	52.4%
TERMINAL (d)	17/35 (49%)	27/40 (68%)	23/40 (58%)	20/40 (50%)
FIRST INCIDENCE	547	446	442	420
HC TUMORS SAME RTE	26/50 (52%)			
HC TUMORS ALL RTEs	629/1249 (50%)			

STATISTICAL TESTS

POLY 3	P=0.085N	P=0.091	P=0.342	P=0.377N
POLY 1.5	P=0.084N	P=0.076	P=0.312	P=0.392N
POLY 6	P=0.090N	P=0.106	P=0.372	P=0.373N
COCH-ARM / FISHERS	P=0.086N	P=0.048*	P=0.272	P=0.421N
MAX-ISO-POLY-3	P=0.140N	P=0.066	P=0.273	P=0.303N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTEs	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
 Androstenedione
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008
 Time Report Requested: 12:55:58
 First Dose M/F: 12/16/02 / 12/16/02
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**All Organs
 Malignant and Benign Tumors**

TUMOR RATES	#	#	#	#
OVERALL (a)	40/50 (80%)	43/50 (86%)	43/50 (86%)	38/50 (76%)
POLY-3 RATE (b)	40/47.93	43/49.61	43/49.01	38/47.7
POLY-3 PERCENT (g)	83.5%	86.7%	87.7%	79.7%
TERMINAL (d)	28/35 (80%)	34/40 (85%)	34/40 (85%)	33/40 (83%)
FIRST INCIDENCE	443	446	442	420
HC TUMORS SAME RTE	39/50 (78%)			
HC TUMORS ALL RTEs	939/1249 (75%)			

STATISTICAL TESTS

POLY 3	P=0.227N	P=0.435	P=0.377	P=0.413N
POLY 1.5	P=0.204N	P=0.400	P=0.336	P=0.406N
POLY 6	P=0.272N	P=0.457	P=0.420	P=0.444N
COCH-ARM / FISHERS	P=0.168N	P=0.298	P=0.298	P=0.405N
MAX-ISO-POLY-3	P=0.322N	P=0.328	P=0.275	P=0.313N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTEs	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS
Androstenedione
CAS Number: 63-05-8

Date Report Requested: 05/09/2008
Time Report Requested: 12:55:58
First Dose M/F: 12/16/02 / 12/16/02
Lab: SRI

LEGEND

- (a) Number of tumor-bearing animals/number of animals examined at site.
 - (b) Number of tumor-bearing animals/Poly-3 number
 - (d) Observed incidence at terminal kill.
 - (e) Value of Statistic cannot be computed.
 - (f) Beneath the control incidence are the P-values associated with the trend test. Beneath the dosed group incidence are the P-values corresponding to pairwise comparisons between the controls and that dosed group.
 - (g) Poly-3 adjusted lifetime tumor incidence.
 - (h) Value of Historical Controls statistic is only calculated when Poly-3 trend is positive and when there is more than one tumor in the treatment groups.
 - (I) Interim sacrifice
 - (T) Terminal sacrifice
 - # Tumor rates based on numbers of animals necropsied.
 - * To the right of any statistical result, indicates significance at ($P \leq 0.05$).
 - ** To the right of any statistical result, indicates significance at ($P \leq 0.01$).
 - N Indicates a negative trend for all tests
- The Cochran-Armitage and Fishers exact tests compare directly the overall incidence rates.

*** END OF REPORT ***